ESMO Expert Dialogue | From Chinese Innovation to Global Consensus — Landmark Interpretation of TALENTOP and New Horizons in Perioperative Therapy for Liver Cancer

ESMO Expert Dialogue | From Chinese Innovation to Global Consensus — Landmark Interpretation of TALENTOP and New Horizons in Perioperative Therapy for Liver Cancer

2026.02.04
Hepatocellular carcinoma (HCC) remains one of the deadliest malignancies worldwide. Approximately 60–70% of patients are diagnosed at intermediate or advanced stages, making the pursuit of innovative therapeutic strategies that deliver meaningful survival benefit a long-standing global challenge. Against this backdrop, the TALENTOP study, led by Fan Jia, Academician and Principal Investigator from Zhongshan Hospital, Fudan University, and presented orally at ESMO 2025 by Sun Huichuan, has drawn worldwide attention.
ESMO Global Perspective | Professor Denis Soulieres: Lessons From the BURAN Trial and the Road Ahead After Immunotherapy Failure in HNSCC

ESMO Global Perspective | Professor Denis Soulieres: Lessons From the BURAN Trial and the Road Ahead After Immunotherapy Failure in HNSCC

2026.02.03
The Phase III BURAN trial, presented at the recent ESMO Congress, evaluated the PI3K inhibitor buparlisib plus paclitaxel in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) who had progressed after PD-1/PD-L1 inhibitor therapy. The study failed to demonstrate improvements in progression-free survival (PFS) or overall survival (OS) compared with paclitaxel alone (median PFS: 4.1 months in both arms; median OS: 9.6 vs 9.7 months), despite a higher objective response rate (ORR) with the combination (30.3% vs 20.7%).
ESMO Global Perspective | Professor Arndt Vogel: From First-Line Advanced Disease to the Perioperative Setting—How Immunotherapy Combinations Are Redefining Hepatocellular Carcinoma Care

ESMO Global Perspective | Professor Arndt Vogel: From First-Line Advanced Disease to the Perioperative Setting—How Immunotherapy Combinations Are Redefining Hepatocellular Carcinoma Care

2026.02.03
With the rapid evolution of immunotherapy–targeted therapy combinations, the management of advanced hepatocellular carcinoma (HCC) has entered a new era. Yet for patients with traditionally high-risk features—such as macrovascular invasion or extrahepatic spread—clinical outcomes have historically remained poor, posing a persistent therapeutic challenge.
[The Lancet] Professor Yungang Tao: Breaking Two Decades of Stagnation—The NIVOPOST-OP Trial Redefines Postoperative Adjuvant Therapy for High-Risk Head and Neck Squamous Cell Carcinoma

[The Lancet] Professor Yungang Tao: Breaking Two Decades of Stagnation—The NIVOPOST-OP Trial Redefines Postoperative Adjuvant Therapy for High-Risk Head and Neck Squamous Cell Carcinoma

2026.02.03
For patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC) at high postoperative risk, the standard of adjuvant concurrent chemoradiotherapy (CRT) has remained unchanged since 2004—despite persistent rates of recurrence and metastasis. Recently, the NIVOPOST-OP trial, led by Yungang Tao of Gustave Roussy Cancer Center, was published in The Lancet, delivering the first definitive breakthrough in nearly 20 years.
Yixian Breast Cancer Conference 2025 | Professor Chang Gong: Stratified Optimization and Precision Escalation/De-Escalation in HER2-Positive Breast Cancer

Yixian Breast Cancer Conference 2025 | Professor Chang Gong: Stratified Optimization and Precision Escalation/De-Escalation in HER2-Positive Breast Cancer

2026.01.31
HER2-positive breast cancer was once associated with aggressive behavior and poor prognosis. However, with the rapid advancement of targeted therapies—particularly antibody–drug conjugates (ADCs)—this subtype has evolved into a highly treatable and potentially curable disease. In 2025, landmark studies across neoadjuvant, adjuvant, and metastatic settings have reshaped treatment paradigms toward greater precision and individualization. During the 2025 Yixian Breast Cancer Conference and CSCO BC South Forum, Oncology Frontier interviewed Professor Chang Gong from Sun Yat-sen Memorial Hospital, Sun Yat-sen University, who summarized the most impactful annual advances in HER2-positive breast cancer treatment.
2025 Yixian Breast Cancer Conference | Professor Kun Wang: Immunotherapy, Chemotherapy, and ADCs Advancing in Parallel to Drive Continued Breakthroughs in Triple-Negative Breast Cancer Outcomes

2025 Yixian Breast Cancer Conference | Professor Kun Wang: Immunotherapy, Chemotherapy, and ADCs Advancing in Parallel to Drive Continued Breakthroughs in Triple-Negative Breast Cancer Outcomes

2026.01.31
The 2025 Yixian Breast Cancer Conference, held alongside the 2025 CSCO Breast Cancer Southern Forum, the Second Chinese Young Breast Cancer Consensus Conference, and the Fourth Yixian Breast Cancer Nursing Conference, took place in Guangzhou on December 26–27, 2025. The meeting focused on standardization of breast cancer care, emerging therapeutic strategies, and precision management in young breast cancer patients, highlighting the latest scientific advances and future clinical directions.
Northern Breast Cancer Forum 2026 | Professor Peng Yuan: Driving Clinical Transformation Through “Three New Forces” and Anticipating Key Updates in the 2026 CSCO Breast Cancer Guidelines

Northern Breast Cancer Forum 2026 | Professor Peng Yuan: Driving Clinical Transformation Through “Three New Forces” and Anticipating Key Updates in the 2026 CSCO Breast Cancer Guidelines

2026.01.31
As China’s flagship academic event in breast cancer at the start of each year, the Northern Breast Cancer Forum continues to bridge global scientific advances with localized clinical practice. From the SERENA-6 trial, which pioneers molecular monitoring for endocrine resistance, to the rapid rise of Trop-2–targeted ADCs and expanded access to PI3K/AKT/mTOR pathway inhibitors under national insurance coverage, the past year has witnessed profound shifts in breast cancer management.
Professor Yongsheng Wang: What Has Changed—and What Remains—in Breast Cancer Surgery?

Professor Yongsheng Wang: What Has Changed—and What Remains—in Breast Cancer Surgery?

2026.01.31
Breast cancer has recently surpassed lung cancer as the most commonly diagnosed cancer among women worldwide. The status of regional lymph node involvement remains a key prognostic factor, directly influencing disease staging, treatment planning, and survival outcomes. While axillary lymph node dissection (ALND) has long been the standard for staging, it carries substantial morbidity. As modern breast surgery moves toward precision and minimally invasive approaches, sentinel lymph node biopsy (SLNB) has replaced ALND as the preferred axillary staging strategy, significantly reducing surgical trauma and complications.